Senti Biosciences (NASDAQ:SNTI) Receives “Buy” Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Senti Biosciences (NASDAQ:SNTI) in a research report report published on Monday morning,Benzinga reports. Chardan Capital currently has a $10.00 price target on the stock.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $10.00 on Monday. The firm has a 50 day simple moving average of $2.37 and a 200 day simple moving average of $2.63. Senti Biosciences has a 52 week low of $1.52 and a 52 week high of $16.94. The company has a market cap of $45.89 million, a PE ratio of -0.64 and a beta of 2.74.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.